On Monday, Bicara Therapeutics Inc (NASDAQ: BCAX) was 5.60% up from the session before settling in for the closing price of $10.53. A 52-week range for BCAX has been $7.80 – $28.09.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 41.07%. With a float of $30.84 million, this company’s outstanding shares have now reached $54.53 million.
The firm has a total of 55 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Bicara Therapeutics Inc (BCAX) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Bicara Therapeutics Inc stocks. The insider ownership of Bicara Therapeutics Inc is 43.44%, while institutional ownership is 62.62%. The most recent insider transaction that took place on Jun 16 ’25, was worth 165,096. In this transaction Chief Legal Officer of this company sold 15,829 shares at a rate of $10.43, taking the stock ownership to the 0 shares. Before that another transaction happened on Jun 16 ’25, when Company’s Officer proposed sale 31,658 for $10.84, making the entire transaction worth $343,173.
Bicara Therapeutics Inc (BCAX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 41.07% per share during the next fiscal year.
Bicara Therapeutics Inc (NASDAQ: BCAX) Trading Performance Indicators
You can see what Bicara Therapeutics Inc (BCAX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 24.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.70, a number that is poised to hit -0.55 in the next quarter and is forecasted to reach -2.70 in one year’s time.
Technical Analysis of Bicara Therapeutics Inc (BCAX)
Analysing the last 5-days average volume posted by the [Bicara Therapeutics Inc, BCAX], we can find that recorded value of 0.37 million was lower than the volume posted last year of 0.63 million. As of the previous 9 days, the stock’s Stochastic %D was 20.23%.
During the past 100 days, Bicara Therapeutics Inc’s (BCAX) raw stochastic average was set at 39.43%, which indicates a significant decrease from 44.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.63 in the past 14 days, which was lower than the 1.13 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.47, while its 200-day Moving Average is $14.50.
